Home LiteratureArticle Details
PMID: 14576155 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

The Journal of biological chemistry ·Vol. 279 ·No. 4 ·2004-01-23 ·Pages 2737-46

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK

Abstract

Prior work demonstrates that AKT activity regulates sensitivity of cells to G(1) arrest induced by mammalian target of rapamycin (mTOR) inhibitors such as rapamycin and CCI-779. To investigate this, a novel high-throughput microarray polysome analysis was performed to identify genes whose mRNA translational efficiency was differentially affected following mTOR inhibition. The analysis also allowed the assessment of steady-state transcript levels. We identified two transcripts, cyclin D1 and c-myc, which exhibited differential expression in an AKT-dependent manner: High levels of activated AKT resulted in rapamycin-induced down-regulation of expression, whereas low levels resulted in up-regulation of expression. To ectopically express these proteins we exploited the finding that the p27(kip1) mRNA was efficiently translated in the face of mTOR inhibition irrespective of AKT activity. Thus, the p27(kip1) 5'-untranslated region was fused to the cyclin D1 and c-myc coding regions and these constructs were expressed in cells. In transfected cells, expression of cyclin D1 or c-myc was not decreased by rapamycin. Most importantly, this completely converted sensitive cells to a phenotype resistant to G(1) arrest. Furthermore, the AKT-dependent differential expression patterns of these two genes was also observed in a mouse xenograft model following in vivo treatment with CCI-779. These results identify two critical downstream molecular targets whose expression is regulated by AKT activity and whose down-regulation is required for rapamycin/CCI-779 sensitivity.

MeSH Terms
Cell Line Cyclin D1/biosynthesis,genetics G1 Phase/drug effects,genetics Gene Expression Regulation/drug effects Genes, myc Humans Protein Kinase Inhibitors Protein Kinases/genetics Protein Serine-Threonine Kinases Proto-Oncogene Proteins/antagonists & inhibitors,genetics Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-myc/biosynthesis,genetics Signal Transduction/drug effects Sirolimus/analogs & derivatives,pharmacology TOR Serine-Threonine Kinases
Chemicals
Protein Kinase Inhibitors Proto-Oncogene Proteins Proto-Oncogene Proteins c-myc Cyclin D1 temsirolimus Protein Kinases MTOR protein, human mTOR protein, mouse AKT1 protein, human Protein Serine-Threonine Kinases Proto-Oncogene Proteins c-akt TOR Serine-Threonine Kinases Sirolimus
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gera Joseph F
Department of Medicine, West Los Angeles Veteran's Administration-UCLA Medical Center, University of California School of Medicine, Los Angeles, California 90073, USA. gera@ucla.edu
Mellinghoff Ingo K
Shi Yijiang
Rettig Matthew B
Tran Chris
Hsu Jung-hsin
Sawyers Charles L
Lichtenstein Alan K
Article Info
Journal
The Journal of biological chemistry
Abbr.
J Biol Chem
ISSN
0021-9258
Published
2004-01-23
Epub
2003-00-23
Pages
2737-46
Language
English
Region
United States
NLM ID
2985121R
Subset
IM
Grants
NCI NIH HHS · CA096920 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com